A Phase 1 Study of the Safety of AAV2/8-LSPhGAA in Late-onset Pompe Disease
Phase of Trial: Phase I/II
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs ACTUS 101 (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Sponsors Actus Therapeutics; Asklepios BioPharmaceutical
- 22 Jan 2019 According to the Actus Therapeutics media release, first patient has been dosed in this trial.
- 22 Jan 2019 Status changed from not yet recruiting to recruiting, according to the Actus Therapeutics media release.
- 21 May 2018 Status changed from planning to not yet recruiting.